The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...
Esketamine (Spravato; Johnson & Johnson) is now the first and only monotherapy for adults with major depressive disorder (MDD ...
One-third of folks with major depressive disorder experience treatment-resistant depression (TRD), a condition that makes it ...
Johnson & Johnson has announced a major breakthrough in mental health treatment. The Food and Drug Administration (FDA) has approved Spravato, a novel nasal spray, for the standalone treatment of ...
The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...
The FDA approved esketamine (Spravato) nasal spray as monotherapy for adults with treatment-resistant depression who had an ...
and Major Depressive Disorder (MDD) with acute suicidal ideation or behavior. We offer Spravato intranasal esketamine and intramuscular ketamine treatment therapy to patients in western North ...
Shares in Axsome Therapeutics have rocketed on FDA approval of its depression therapy Auvelity (formerly AXS-05) – a year after its approval was held up by the regulator. The FDA has cleared ...
Spravato (esketamine) has been touted as a potential ... offer new hope to the estimated one-third of people with major depressive disorder who have not responded to existing therapies,” said ...
Borderline personality disorder (BPD) is diagnosed in 10-30% of patients with major depressive disorder ... who received 5 intravenous infusions of esketamine (25-50mg) within 2 weeks. Initially, a ...
We identified 32 studies that met our inclusion criteria. Results: We found that the relative risk of developing a depressive disorder was incidence rate ratio = 0.79 (95% confidence interval ...